Earnings release
Page 1
ourofino | Tá bem saúde animal Results 2Q26 Earnings Conference Call August 7 , 2026 ( Friday ) 11:00 a.m. BRT Portuguese with simultaneous English translation
Page 2
ri.ourofino.com 2 Results 2Q26 X’ Cravinhos, August 6, 2026 Ourofino S.A. ("Company" or "Ourofino") (B3: OFSA3), a company engaged in the research, development, manufacturing and commercialization of veterinary medicines, vaccines and other products for production and companion animals, today announces its financial results for the period ended June 30, 2026 (2Q26). Financial and operating information is presented in millions of Brazilian reais, unless otherwise stated. Investor Relations Department ri@ourofino.com (16) 3518-2000 ri.ourofino.com Marcelo Silva Philipe Villa Lislaine Oliveira & RI team Results 2Q26
Page 3
ri.ourofino.com 3 Results 2Q26 | Highlights ▪ Consolidated net revenue reached R$338.7 million in 2Q26, up 30.7% compared to 2Q25, and totaled R$589.1 million in 6M26, an increase of 31.3% compared to 6M25. ▪ In Production Animals, net revenue reached R$252.4 million in 2Q26, up 28.2% compared to 2Q25, and totaled R$428.8 million in 6M26, an increase of 33.1% compared to 6M25. ▪ In Companion Animals, net revenue reached R$49.8 million in 2Q26, up 44.8% compared to 2Q25, and totaled R$94.9 million in 6M26, an increase of 33.7% compared to 6M25. ▪ In International Operations, net revenue totaled R$36.5 million in 2Q26, up 30.5% compared to 2Q25, and reached R$65.4 million in 6M26, an increase of 17.9% compared to 6M25. ▪ Consolidated gross profit reached R$167.4 million in 2Q26, up 25.6%, with a gross margin of 49.4%, down 2.0 p.p. compared to 2Q25. In 6M26, gross profit totaled R$302.4 million, up 34.3%, with a gross margin of 51.3%, representing an expansion of 1.2 p.p. compared to 6M25. ▪ Adjusted EBITDA reached R$60.8 million in 2Q26, up 22.1% compared to 2Q25, and totaled R$105.4 million in 6M26, an increase of 54.0% compared to 6M25. ▪ Adjusted Net Income reached R$15.9 million in 2Q26, down 33.3%, and R$36.7 million in 6M26, up 41.7%. ▪ Leverage ended 2Q26 at 0.43x Net Debt/LTM Adjusted EBITDA, compared to 0.85x at year-end 2025, with 87.0% of debt classified as long-term and an average cost of debt of 8.69%, compared to 8.23% at year-end 2025. ▪ At the 2026 Valor Inovação Brasil Awards, held on August 3, Ourofino Saúde Animal was recognized as one of the most innovative companies in Brazilian agribusiness, ranking second in its industry category.
Page 4
ri.ourofino.com 4 Results 2Q26 MANAGEMENT MESSAGE We concluded the first half of 2026 with consistent results, revenue growth across all business segments, and continued improvement in key operating and financial indicators. This performance reflects the successful execution of our sustainable growth stra tegy, supported by portfolio expansion, commercial discipline, efficient cost management, and the allocation of resources to initiatives aligned with the Company's strategic priorities. In 2Q26, net revenue reached R$338.7 million, up 30.7% compared to 2Q25. In 6M26, net revenue totaled R$589.1 million, representing growth of 31.3%. Gross profit reached R$167.4 million in the quarter and R$302.4 million in the first half, increasing 25.6% and 34.3%, respectively. Adjusted EBITDA totaled R$60.8 million in the quarter and R$105.4 million in the first half, growing 22.1% and 54.0%, respectively. Adjusted Net Income amounted to R$15.9 million in 2Q26 and R$36.7 million in 6M26. In the first ha lf, earnings increased 41.7% compared to 6M25, supported by strong commercial performance, portfolio development, and margin and profitability gains achieved throughout the period. Quarterly results were affected by the discontinuation of certain Companion Animals development projects, which resulted in the recognition of a R$24.4 million accounting provision related to intangible assets. This decision reflects the prioritization of projects with greater alignment to the Company's strategy and stronger value creation prospects. Results were also impacted by inventory loss provisions substantially associated with deviations identified in the manufacturing process. Although these events affected quarterly earnings, they are non -recurring in nature and do not alter the Company's operating fundamentals or long-term growth prospects. In Production Animals , net revenue reached R$252.4 million in 2Q26 and R$428.8 million in 6M26, representing growth of 28.2% and 33.1%, respectively. Gross profit totaled R$193.7 million, up 36.9%, with a 1.3 p.p. expansion in gross margin, even considering the inventory provi sions related to manufacturing process deviations. The segment continued to benefit from products launched in 2025, which increased their participation in the portfolio, supported by commercial initiatives undertaken throughout the period. Recent product l aunches continue to deliver strong performance and strengthen the Company's competitive position in strategic markets. In Companion Animals , net revenue reached R$49.8 million in 2Q26 and R$94.9 million in 6M26, increasing 44.8% and 33.7%, respectively. Gross profit totaled R$66.9 million in the first six months of the year, representing growth of 39.6% and a 3.0 p.p. expansion in gross margi n. Performance reflected successful commercial execution and the continued advancement of WellPet in the market, contributing to portfolio expansion, strengthening the Company's presence in the segment, and enhancing profitability. In International Operations, net revenue totaled R$36.5 million in 2Q26 and R$65.4 million in 6M26, increasing 30.5% and 17.9%, respectively. Gross profit reached R$41.8 million in 6M26, maintaining a gross margin of 63.8%. We highlight the strong performance in the Mexican market and the expansion of commercial activities across other Latin American countries, reinforcing the Company's international growth strategy. It is also important to highlight that business growth has been accompanied by strong operating cash generation. In 6M26, the Company generated R$183.7 million in operating cash flow, ending the period with R$369.0 million in cash, financial investments, and cash equivalents. Leverage reached 0.43x Net Debt/LTM EBITDA, reinforcing our ability to finance growth and support our investment agenda focused on innovation and business expansion.
Page 5
ri.ourofino.com 5 Results 2Q26 We remain focused on executing our strategic plan by combining growth, innovation, operational efficiency, and disciplined capital allocation. Our first half results reinforce our ability to expand revenue, strengthen profitability, and generate cash. This progress is accompanied by the consistency of our innovation agenda, which was once again recognized with second place in the Agribusiness category of the 2026 Valor Inovação Brasil ranking , organized by Valor and Época Negócios and announced after the reporting period. This achievement adds to the recognition recently received by the Company and further demonstrates our ability to develop solutions that create value. We will continue investing in business expansion and increasing our market presence, while maintaining animal health and well-being as a fundamental part of our purpose and our commitment to sustainable long-term value creation. With Ourofino, they are in good hands. Kleber Gomes Marcelo da Silva Chief Executive Officer Chief Financial Officer & Investor Relations Director
Page 6
ri.ourofino.com 6 Results 2Q26 Financial Highlights
Page 7
ri.ourofino.com 7 Results 2Q26 CONSOLIDATED NET REVENUE AND GROSS PROFIT In 2Q26, consolidated net revenue reached R$338.7 million, up 30.7% compared to 2Q25, while gross profit increased 25.6% to R$167.4 million, with a gross margin of 49.4%. In 6M26, net revenue reached R$589.1 million, an increase of 31.3%, while gross profit totaled R$302.4 million, up 34.3%, with a 1.2 p.p. expansion in gross margin to 51.3%. Revenue growth in 6M26 reflected, among other factors, the contribution from products launched throughout 2025, accompanied by gross margin expansion during the period. In 2Q26, however, profitability was partially affected by inventory loss provisions, primarily related to deviations identified in the manufacturing process. + 55,9% + 30,7% + 48,9% + 31,3% R$ million
Page 8
ri.ourofino.com 8 Results 2Q26 PRODUCTION ANIMALS The Production Animals business unit reported net revenue of R$252.4 million in 2Q26, up 28.2% compared to 2Q25, while gross profit reached R$110.8 million, an increase of 20.4%, with a gross margin of 43.9%, down 2.8 p.p. In 6M26, net revenue totaled R$428.8 million, up 33.1% compared to 6M25, while gross profit reached R$193.7 million, an increase of 36.9%, with gross margin expanding by 1.3 p.p. to 45.2%. In 6M26, this performance reflected the contribution of products launched throughout 2025, which increased their share of the portfolio, combined with commercial initiatives and a more favorable sales mix. In the quarter, margin was partially impacted by i nventory loss provisions, primarily associated with deviations identified in the manufacturing process. + 64.0% + 28.2% + 53.5% + 33.1% R$ million
Page 9
ri.ourofino.com 9 Results 2Q26 COMPANION ANIMALS The Companion Animals business unit reported net revenue of R$49.8 million in 2Q26, up 44.8% compared to 2Q25. Gross profit reached R$34.9 million, an increase of 50.3%, with a gross margin of 70.2%, representing an expansion of 2.6 p.p. In 6M26, net revenue totaled R$94.9 million, up 33.7%, while gross profit reached R$66.9 million, an increase of 39.6%, with a gross margin of 70.5%, representing an expansion of 3.0 p.p. Performance reflected the commercial initiatives carried out during the period and the Company's entry into the canine ectoparasiticide therapeutic category through the launch of WellPet, expanding its portfolio and strengthening its presence in the Companion Animals market. + 39.1% + 44.8% + 36.4% + 33.7% R$ million
Page 10
ri.ourofino.com 10 Results 2Q26 INTERNATIONAL OPERATIONS The International Operations business unit reported net revenue of R$36.5 million in 2Q26, up 30.5% compared to 2Q25. Gross profit totaled R$21.6 million, an increase of 19.3%, with a gross margin of 59.2%, down 5.4 p.p. In 6M26, net revenue reached R$65.4 million, up 17.9% compared to 6M25, while gross profit totaled R$41.8 million, an increase of 16.9%, with a gross margin of 63.8%, down 0.5 p.p. This performance was supported by the strong results of the Company's operations in Mexico and by commercial initiatives undertaken across Latin American markets, contributing to the expansion of the Company's international presence. + 32.7% + 30.5% + 40.6% + 17.9% R$ million
Page 11
ri.ourofino.com 11 Results 2Q26 Selling, General and Administrative Expenses (SG&A) R$ Million 2Q25 2Q26 Chg % 6M25 6M26 Chg % Selling, General & Administrative Expenses (SG&A) (76.6) (96.0) 25.3% (145.7) (176.7) 21.2% (-) Non-Recurring Event Adjustments¹ 0.3 0.0 - 0.3 0.0 - Adjusted Selling, General and Administrative Expenses (Adjusted SG&A) (76.3) (96.0) 25.8% (145.4) (176.7) 21.5% Percentages of Net Revenue -29.4% -28.4% 1.0 p.p. -32.4% -30.0% 2.4 p.p. ¹ In 2Q25 and 6M25, non-recurring adjustments refer to extraordinary expenses related to strategic consulting services. In 2Q26, adjusted selling, general and administrative expenses totaled R$96.0 million, compared to R$76.3 million in 2Q25, representing growth of 25.8%. As this increase was below net revenue growth of 30.7%, the ratio of these expenses to net revenue decreased from 29.4% to 28.4%, resulting in a dilution of 1.0 p.p. In 6M26, adjusted selling, general, and administrative expenses totaled R$176.7 million, compared to R$145.4 million in 6M25, representing growth of 21.5%. During the same period, net revenue increased by 31.3%, causing the ratio of these expenses to net revenue to decline from 32.4% to 30. 0%, resulting in a dilution of 2.4 p.p. The changes observed during the periods were mainly attributable to: (i ) strategic investments in commercial and marketing structures, in line with the Company's strategic objectives; and (ii) the impact of wage agreement adjustments implemented between the periods. OTHER EXPENSES R$ Million 2Q25 2Q26 Chg % 6M25 6M26 Chg % Other expenses (0.0) (23.5) - (1.2) (24.8) - (-) Adjustments for Non-Recurring Events¹ (1.0) 21.3 - (0.3) 21.3 - Other expenses adjusted (1.0) (2.2) 115.8% (1.5) (3.5) 128.6% Percentages of Net Revenue -0.4% -0.6% -0.2 p.p. -0.3% -0.6% -0.3 p.p. ¹ In 2Q25 and 6M25, non -recurring adjustments refer to prior -period tax credits. In 2Q26 and 6M26, non -recurring adjustments refer to prior-period tax credits and an impairment provision related to intangible assets. In 2Q26, the Company decided to discontinue certain Companion Animals projects, resulting in the recognition of R$24.4 million in impairment losses on the related assets. For comparability purposes, these effects were adjusted within Other Expenses. These decisions do not alter the Group’s growth strategy, which remains focused on innovation, portfolio expansion and the development of priority markets, in line with the strategic plan.
Page 12
ri.ourofino.com 12 Results 2Q26 % of net revenue % of net revenue
Page 13
ri.ourofino.com 13 Results 2Q26 Research and Innovation Expenses In 6M26, we invested R$40.4 million in research and development, of which R$36.9 million was recognized as expenses, reflecting both the stage of development of the projects and their associated level of innovation. We maintain a continuous investment agen da in research, development and innovation, and quarterly investment levels may vary according to the different stages and cycles of research activities. + 1.8% + 3.7%
Page 14
ri.ourofino.com 14 Results 2Q26 EBITDA AND EBTIDA MARGIN R$ Million 2Q25 2Q26 Chg % 6M25 6M26 Chg % Adjusted net profit* 23.8 15.9 -33.3% 25.9 36.7 41.7% (+) non-recurrent results* 0.7 4.3 - 0.6 4.2 - (+) Deferred Corporate Income Tax and Social Contribution* (0.2) (1.4) - (0.2) (0.8) - Net Income for the Period 24.3 18.8 -22.7% 26.3 40.1 52.5% (+) Net financial results 4.1 3.5 -14.8% 8.0 4.8 -40.4% (+)Income Tax and Social Contribution* 12.5 7.2 -42.4% 15.0 19.1 27.3% (+) Depreciation and amortization 9.6 10.0 4.2% 19.1 20.0 4.7% EBITDA 50.5 39.5 -21.8% 68.4 84.0 22.7% (+) non-recurrent effects (0.7) (4.3) - (0.6) (4.2) - (+) Others** 0.0 25.5 - 0.6 25.5 - ADJUSTED EBITDA ** 49.8 60.8 22.1% 68.4 105.4 54.0% Net Sales Revenue 259.2 338.7 30.7% 448.8 589.1 31.3% EBITDA margin 19.5% 11.6% -7.9 p.p. 15.2% 14.3% -0.9 p.p. Adjusted EBITDA margin 19.2% 17.9% -1.3 p.p. 15.3% 17.9% 2.6 p.p. * In 2Q25 and 6M25, extraordinary expenses and prior-period tax credits were excluded. In 2Q26 and 6M26, prior-period tax credits were excluded. The corresponding tax effects related to the adjustments presented were also excluded in each period. ** In addition to the adjustments mentioned above, Adjusted EBITDA excludes the impairment provision recognized on intangible assets. Adjusted EBITDA totaled R$60.8 million in 2Q26, representing an increase of 22.1% compared to 2Q25. In the first half of 2026, Adjusted EBITDA reached R$105.4 million, up 54.0% compared to 6M25. In 6M26, the Adjusted EBITDA margin expanded by 2.6 p.p. We highlight the gains in operating efficiency driven by gross margin improvement, as well as the reduction and dilution of adjusted SG&A expenses.
Page 15
ri.ourofino.com 15 Results 2Q26 FINANCIAL RESULTS R$ Million 2Q25 2Q26 Chg % 6M25 6M26 Chg % Net financial results (4.1) (3.5) -14.8% (8.0) (4.8) -40.4% In 2Q26, net financial expenses totaled R$3.5 million, while in 6M26 net financial expenses amounted to R$4.8 million, representing decreases of 14.8% and 40.4%, respectively, compared to the same periods of the previous year. This improvement was mainly driven by higher income from financial investments, resulting from a higher average balance of cash, cash equivalents and financial investments. INCOME TAX AND SOCIAL CONTRIBUTION R$ Million 2Q25 2Q26 Chg % 6M25 6M26 Chg % Income tax and social contribution (12.5) (7.3) -41.7% (15.1) (19.2) 27.3% Percentage of Profit Before Income Tax and Social Contribution 34.0% 28.0% -6.0 p.p. 36,4% 32,4% -4.1 p.p. Income tax and social contribution expenses totaled R$19.2 million in 6M26, representing an increase of 27.3% compared to 6M25. The effective tax rate was 32.3%, compared to 36.4% in the same period of the previous year. The calculation of income taxes considers the differences between accounting income and the corresponding taxable income bases. ADJUSTED NET PROFIT R$ Million 2Q25 2Q26 Chg % 6M25 6M26 Chg % Adjuste net profit 23.8 15.9 -33.3% 25.9 36.7 41.7% Margin 9.2% 4.7% -4.5 p.p. 5.8% 6.2% +0.5 p.p. As a result of the factors discussed above, Adjusted Net Income totaled R$15.9 million in 2Q26 and R$36.7 million in 6M26, representing a decrease of 33.3% and an increase of 41.7%, respectively, compared to the same periods of the previous year.
Page 16
ri.ourofino.com 16 Results 2Q26 CASH POSITION The Company started 2026 with R$250.8 million in cash and cash equivalents. During the first half of the year, operating cash generation totaled R$183.7 million, reflecting the strong cash generation capacity of its operations. Financing activities resulted in a net cash outflow of R$56.1 million, primarily related to interest payments, amortization of loans and financing, and other financial disbursements during the period. In addition, the Company invested R$8.5 million in CAPEX and intangible assets. During the first half, the Company also transferred R$148.1 million to an exclusive investment fund. This fund was established solely to receive investments from the Company and its subsidiaries. The fund's units have daily liquidity, with no lock-up period for redemption, and are settled on a D+0 basis, subject to the terms and conditions set forth in the fund's regulations. The fund is administered by S3 Caceis Brasil DTVM S.A. and managed by Santander Brasil Gestão de Recursos Ltda. As a result, the Company ended 2Q26 with R$369.0 million in cash and cash equivalents, maintaining an adequate liquidity position to support its operations and investment plan. ¹ Operating cash generation differs from the amount presented in the Statement of Cash Flows due to accrued income on financial investments the, which isluded in the ending balance of those investments.
Page 17
ri.ourofino.com 17 Results 2Q26 INDEBTNESS R$ million 12M25 2Q26 Current Assets 52.1 65.8 Non-current Assets 437.4 440.3 Gross Debt 489.6 506.1 (-) Cash, Cash Equivalents and Financial Investments (250.8) (369.0) Dívida Líquida 238.8 137.1 Custo médio da dívida (ano) 8.23% 8.69% Dívida líquida/EBITDA anual ajustado LTM 0.85x 0.43x In 2Q26, gross debt totaled R$506.1 million, representing an increase of 3.4% compared to December 2025. Net debt, in turn, decreased from R$238.8 million to R$137.1 million, benefiting from the R$18 3.7 million in operating cash generation recorded during the first half of the year. Financial leverage ended the period at 0.43x Net Debt/LTM Adjusted EBITDA. The gross debt profile remains well aligned with the Company's investment agenda, with 87.0% of maturities classified as long-term, of which 34.1% mature in more than five years.
Page 18
ri.ourofino.com 18 Results 2Q26 The average cost of debt at the end of the period was 8.69%, representing a spread of 5.46 percentage points below the 14.15% Selic rate observed during the same period. Cost of debt Selic
Page 19
ri.ourofino.com 19 Results 2Q26
Page 20
ri.ourofino.com 20 Results 2Q26 STATUTORY INCOME STATEMENT Income Statement (R$ thousands) 2Q25 2Q26 6M25 6M26 Net revenue 259,194 338,673 448,760 589,142 Cost of goods sold (125,898) (171,253) (223,608) (286,780) Gross profit 133,296 167,420 225,152 302,362 Sales expenses (60,395) (78,427) (113,644) (142,321) Research and development expenses (15,822) (18,426) (28,850) (36,855) General and administrative expenses (16,215) (17,561) (32,083) (34,350) Other expenses, net (42) (23,531) (1,181) (24,799) Operational profit 40,822 29,475 49,394 64,037 Financial revenues 4,604 11,147 8,709 21,198 Financial expenses (8,746) (13,601) (16,647) (24,773) Net Derivative Financial Instruments (3,344) (1,000) (3,230) (229) Net Foreign Exchange Gains and Losses 3,421 (11) 3,119 (993) Financial Result (4,065) (3,465) (8,049) (4,797) Profit Before Income Tax and Social Contribution 36,757 26,010 41,345 59,240 Income Tax and Social Contribution - Current and Deferred (12,514) (7,293) (15,054) (19,166) Net Income for the Period 24,243 18,717 26,291 40,074
Page 21
ri.ourofino.com 21 Results 2Q26 STATEMENT OF CASHFLOWS (1/2) Statement of cashflows (R$ thousands) 6M25 6M26 Cash Flows from Operating Activities Net Income for the Period 26,291 40,074 Adjustments for: Current and Deferred Income Tax and Social Contribution 15,054 19,166 Expected Credit Losses (Gains) Losses (26) 838 Provision for Inventory Write-Downs and Losses 13,615 17,586 Depreciation and Amortization 19,032 20,033 Provision for Impairment of Intangible Assets 654 21,271 Gain (Loss) on Disposal of Property, Plant and Equipment (116) (60) Gain (Loss) on Disposal of Intangible Assets. (666) 4,295 Net Monetary, Foreign Exchange and Interest Variations 11,976 19,999 Derivative Financial Instruments 3,230 229 Provision (Reversal) for Legal Proceedings (225) 1,453 Long-Term Incentives 2,573 (3,184) Present Value Adjustment 1,207 1,301 Changes in Working Capital Trade Accounts Receivable 116,574 236,077 Inventories (156,655) (78,463) Recoverable Taxes 361 (9,329) Other Assets (7,075) (4,413) Trade Payables 39,552 (77,765) Taxes Payable (5,111) 2,793 Other Liabilities (6,975) 4,807 Cash Generated from Operations 73,270 216,708 Interest Paid on Loans and Borrowings (12,091) (16,971) Interest Paid on Lease Liabilities (747) (1,524) Income Tax and Social Contribution Paid (9,965) (15,473) Net Cash Generated from Operating Activities 50,467 182,740
Page 22
ri.ourofino.com 22 Results 2Q26 STATEMENT OF CASHFLOWS (2/2) Statement of cashflows (R$ thousands) 6M25 6M26 Cash Flows from Investing Activities Investments in Financial Investments - (148,090) Investments in Intangible Assets (10,792) (3,529) Acquisition of Property, Plant and Equipment (PP&E) (13,630) (5,250) Proceeds from the Sale of Property, Plant and Equipment 965 232 Proceeds from the Sale of Intangible Assets 667 0 Net Cash Used in Investing Activities (22,790) (156,637) Cash Flows from Financing Activities Proceeds from Loans and Borrowings 67,500 29,992 Repayment of Loans and Borrowings (21,060) (18,016) Lease Payments (3,434) (4,356) Return of Capital to Shareholders (120,134) 0 Payment of Dividends and Interest on Equity (35,000) (62,885) Settled Derivative Financial Instruments (1,480) (880) Net Cash Used in Financing Activities (113,608) (56,145) Net Increase (Decrease) in Cash and Cash Equivalents (85,931) (30,042) Cash and Cash Equivalents at the Beginning of the Period 233,957 250,821 Foreign Exchange Gains (Losses) on Cash and Cash Equivalents (427) (802) Cash and Cash Equivalents at the End of the Period 147,599 219,977
Page 23
ri.ourofino.com 23 Results 2Q26 BALANCE SHEET – ASSETS Balance sheet (R$ thousands) 12/31/2025 06/30/2026 Assets Current Assets 1,023,334 1,106,842 Cash and cash equivalents 250,821 219,977 Short-Term Investments - 149,026 Derivative Financial Instruments - 428 Trade Receivables 430,367 327,134 Inventories and Advances to Suppliers 312,128 375,278 Recoverable Taxes 4,628 11,228 Recoverable Income Tax and Social Contribution 12,198 5,994 Related Parties 182 250 Other Assets 13,010 17,527 Non-Current Assets 542,488 507,670 Long-Term Assets 93,770 93,323 Recoverable Taxes 1,268 1,212 Deferred Income Tax and Social Contribution 78,921 80,647 Inventories and Advances to Suppliers 12,310 10,259 Other Assets 1,271 1,205 Permanent Assets 448,718 414,347 Property, Plant and Equipment 342,882 336,013 Intangible Assets 105,836 78,334 Total Assets 1,565,822 1,614,512
Page 24
ri.ourofino.com 24 Results 2Q26 BALANCE SHEET – LIABILITIES AND SHAREHOLDER’S EQUITY Balance sheet (R$ thousands) 12/31/2025 06/30/2026 Liabilities and Shareholders' Equity Current Liabilities 288,001 306,390 Trade Payables 97,332 146,588 Derivative Financial Instruments 597 398 Loans and Borrowings 52,144 65,810 Salaries and Social Charges 47,687 47,624 Taxes Payable 14,988 12,111 Income Tax and Social Contribution Payable - 2,144 Related Parties 2,153 7,789 Dividends and Interest on Equity 52,799 - Lease Liabilities 7,776 6,898 Sales Commissions 1,218 901 Other Liabilities 11,307 16,127 Non-Current Liabilities 480,964 481,166 Loans and Borrowings 437,439 440,256 Provision for Legal Proceedings 4,969 6,412 Lease Liabilities 6,229 5,354 Other Liabilities 32,327 29,144 Total Liabilities 768,965 787,556 Total Shareholders' Equity 796,857 826,956 Non-Controlling Interests 21 19 Total Liabilities and Shareholders' Equity 1,565,822 1,614,512
Page 25
25 ri.ourofino.com We develop solutions and services that help feed the world and enhance the longevity of companion animals. ourofino.com ri.ourofino.com